NCT05943496 2025-11-06Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaOHSU Knight Cancer InstitutePhase 1 Recruiting27 enrolled